Venus Remedies clinches WHO-backed PAHO tender
The company has been entrusted with the responsibility of supplying a wide range of essential oncology drugs
The company has been entrusted with the responsibility of supplying a wide range of essential oncology drugs
Ukrainian marketing approvals for paclitaxel, oxaliplatin and irinotecan mark a significant milestone in the company’s global expansion strategy
Impressive safety and efficacy for solid cancer patients followed by global clinical study plan
Venus Remedies' oncology wing has also secured marketing authorisation from Myanmar for another chemotherapy drug
With this, the company has secured 511 marketing approvals for its oncology products across 66 countries
The company has secured 506 marketing approvals for its oncology products across 76 countries.
With this, the number of marketing approvals for its oncology products across 75 countries has gone up to 503
UTD2 is the world's first oral epothilone microtubule inhibitor
The company moves a step closer towards achieving its goal of emerging as the top oncology medicine supplier from India in the ASEAN region
Subscribe To Our Newsletter & Stay Updated